BWBen Wan

Ben Wan

*This is an algorithmically generated author record based on publicly available information.

Ben Wan has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • Renxian Wang

    2 shared publications
  • Bowen Zhang

    Laboratory of Bone Tissue Engineering, Beijing Laboratory of Biomedical Materials, Beijing Research Institute of Traumatology and Orthopaedics, Beijing JiShuiTan Hospital, Beijing 100035, China

    1 shared publication
  • Dafu Chen

    1 shared publication
  • Dafu Chen

    Laboratory of Bone Tissue Engineering Beijing Laboratory of Biomedical Materials National Center for Orthopaedics Beijing Research Institute of Traumatology and Orthopaedics Beijing Jishuitan Hospital Capital Medical University Beijing China

    1 shared publication
  • Gang Wang

    1 shared publication
  • Gang Wu

    Savid School of Stomatology, Hangzhou Medical College, Hangzhou, China

    1 shared publication

Latest Publications

  • Harnessing Immunomodulation: How Calcium Phosphate Biomaterials Orchestrate Bone Regeneration

    by Mengyuan Zhang, Ben Wan, Mouyuan Sun, Jiafei Sun, Yi Zhu, Gang Wu, Ping Sun

    The immune system and biomaterials exhibit a well-documented synergistic interplay, essential for bone defect healing. Calcium phosphate (CaP) biomaterials, notably hydroxyapatite, β-tricalcium phosphate, and biphasic calcium phosphate, are widely employed as bone substitutes due to their inherent osteoconductivity. A key challenge for synthetic CaPs is augmenting their osteoinductive potential. Indeed, the limited translation of biomaterials into clinical practice may largely stem from insufficient immunomodulatory understanding. Current evidence reveals the complex host immune response to CaPs, which is mediated by physical and biochemical properties. Harnessing immunomodulatory strategies could bridge inflammatory modulation and osteogenesis, thereby enhancing bone regeneration. This review systematically analyzes recent advances in the molecular mechanisms of immune cell responses to CaPs during bone defect healing, deepening our understanding of immunomodulatory strategies for bone regeneration. Furthermore, key knowledge gaps are highlighted to inspire the development of spatiotemporally responsive CaPs for bone tissue engineering.


  • Open Access

    Regulation of hypoxic stress and oxidative stress in bone grafting: Current trends and future perspectives

    by Hao Hu, Xiao Liu, Jun Chen, Shangbin Cui, Hualin Yi, Gang Wang, Renxian Wang, Tiansheng Zheng, Ben Wan, Zhiyu Zhou, et al.


  • Open Access

    Analysis of Immune Gene Expression Subtypes Reveals Osteosarcoma Immune Heterogeneity

    by Ben Wan, Renxian Wang, Jingjun Nie, Yuyang Sun, Bowen Zhang, Weifeng Liu, Dafu Chen

    Background. Osteosarcoma (OS) patients have a poor response to immunotherapy due to the sheer complexity of the immune system and the nuances of the tumor-immune microenvironment. Methodology. To gain insights into the immune heterogeneity of OS, we identified robust clusters of patients based on the immune gene expression profiles of OS patients in the TARGET database and assessed their reproducibility in an independent cohort collected from the GEO database. The association of comprehensive molecular characterization with reproducible immune subtypes was accessed with ANOVA. Furthermore, we visualized the distribution of individual patients in a tree structure by the graph structure learning-based dimensionality reduction algorithm. Results. We found that 87 OS samples can be divided into 5 immune subtypes, and each of them was associated with distinct clinical outcomes. The immune subtypes also demonstrated widely different patterns in tumor genetic aberrations, tumor-infiltrating, immune cell composition, and cytokine profiles. The immune landscape of OS uncovered the significant intracluster heterogeneity within each subtype and depicted a continuous immune spectrum across patients. Conclusion. The established five immune subtypes in our study suggested immune heterogeneity in OS patients and may provide optimal individual immunotherapy for patients exhibiting OS.